Nevan C. Elam - Dec 28, 2023 Form 4 Insider Report for Savara Inc (SVRA)

Role
Director
Signature
/s/ David Lowrance, as attorney-in-fact for Nevan Elam
Stock symbol
SVRA
Transactions as of
Dec 28, 2023
Transactions value $
-$372,570
Form type
4
Date filed
12/29/2023, 04:33 PM
Previous filing
Dec 15, 2023
Next filing
Jan 25, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SVRA Common Stock Options Exercise $1.44K +1.76K +2.81% $0.82* 64.3K Dec 28, 2023 Direct
transaction SVRA Common Stock Options Exercise $19.1K +12K +18.65% $1.59* 76.3K Dec 28, 2023 Direct
transaction SVRA Common Stock Options Exercise $49.2K +40K +52.4% $1.23* 116K Dec 28, 2023 Direct
transaction SVRA Common Stock Sale -$442K -93.8K -80.66% $4.71 22.5K Dec 28, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SVRA Stock Option (Right to Buy) Options Exercise $0 -1.76K -100% $0.00* 0 Dec 28, 2023 Common Stock 1.76K $0.82 Direct F2
transaction SVRA Stock Option (Right to Buy) Options Exercise $0 -12K -100% $0.00* 0 Dec 28, 2023 Common Stock 12K $1.59 Direct F3
transaction SVRA Stock Option (Right to Buy) Options Exercise $0 -40K -100% $0.00* 0 Dec 28, 2023 Common Stock 40K $1.23 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price is a weighted average sales price. The sale prices ranged from $4.70 to $4.795. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
F2 The shares subject to the option vested and became exercisable in twelve equal quarterly installments beginning on October 24, 2014.
F3 The shares subject to the option vested and became exercisable in twelve equal installments on each quarterly anniversary of December 20, 2019.
F4 The shares subject to the option vested and became exercisable on December 16, 2021.